Beáta Fekete1, Márta Palkó2, Matti Haukka3, Ferenc Fülöp4,5. 1. Institute of Pharmaceutical Chemistry, University of Szeged, Eötvös utca 6, Szeged H-6720, Hungary. fekete.beata@pharm.u-szeged.hu. 2. Institute of Pharmaceutical Chemistry, University of Szeged, Eötvös utca 6, Szeged H-6720, Hungary. palko@pharm.u-szeged.hu. 3. Department of Chemistry, University of Jyväskylä, FIN-40014 Turku, Finland. matti.o.haukka@jyu.fi. 4. Institute of Pharmaceutical Chemistry, University of Szeged, Eötvös utca 6, Szeged H-6720, Hungary. fulop@pharm.u-szeged.hu. 5. MTA-SZTE Stereochemistry Research Group, Hungarian Academy of Sciences, Eötvös utca 6, Szeged H-6720, Hungary. fulop@pharm.u-szeged.hu.
Abstract
From 2-aminonorbornene hydroxamic acids, a simple and efficient method for the preparation of pyrrolo[1,2-a]pyrimidine enantiomers is reported. The synthesis is based on domino ring-closure followed by microwave-induced retro Diels-Alder (RDA) protocols, where the chirality of the desired products is transferred from norbornene derivatives. The stereochemistry of the synthesized compounds was proven by X-ray crystallography. The absolute configuration of the product is determined by the configuration of the starting amino hydroxamic acid.
From 2-aminonorbornene hydroxamic acids, a simple and efficient method for the preparation of pyrrolo[1,2-a]pyrimidine enantiomers is reported. The synthesis is based on domino ring-closure followed by microwave-induced retro Diels-Alder (RDA) protocols, where the chirality of the desired products is transferred from norbornene derivatives. The stereochemistry of the synthesized compounds was proven by X-ray crystallography. The absolute configuration of the product is determined by the configuration of the starting amino hydroxamic acid.
The first hydroxamic acid (oxalohydroxamic acid [1]) was discovered by Lossen as early as 1869. However, hydroxamic acids attracted further attention at the beginning of the 1980s because of their bioactivity [2]. Their pharmacological properties are related to their ability to scavenge metal ions [3]. In addition, they are able to generate nitric oxide [3,4,5] in living systems. In this way, they can act as antimicrobial [6,7,8,9], antitumour [6,10], antihypertensive [11], anti-inflammatory [6,12], and neuroleptic agents, among others [3,13].According to the literature data, aromatic hydroxamic acids are useful compounds [14,15,16,17,18,19,20,21,22,23]. However, only limited information is available about their reactions [24,25] and, in particular, about the properties of alicyclic derivatives [26,27].Though the hydroxamic acid moiety is an important key pharmacophore in most cases, it is usually built up just in the last step of the synthesis [28,29,30]. Previously, we have examined the reactivity and stereoselectivity of the domino reaction of 2-aminonorbornene hydroxamic acids with 2-formylbenzoic acid and 2,3-dimethoxy-6-formylbenzoic acid to form new isoindolo[2,1-a]quinazolines and pyrimido[2,1-a]isoindoles [31].Focusing on the biological potential of fused quinazolinones, and continuing our work on the synthesis of novel N-heterocycles, herein, we report the synthesis of a new series of pyrrolo[1,2-a]quinazolinones and pyrrolo[1,2-a]pyrimidines starting from hydroxamic acids. Pyrroloquinazolines and pyrrolopyrimidines are important heterocyclic ring systems that occur as a core structure in a variety of naturally occurring alkaloids and synthetic compounds. Pyrrolo[1,2-a]quinazolines are tricyclic compounds with great potential and combine the quinazoline substructure, a privileged structure in medicinal chemistry, with a pyrrole [32]. Their synthetic methods are rather scarce but the past five years have brought efficient new synthetic strategies which could lead to an increased interest in pyrrolo[1,2-a]quinazolines in the near future, mainly for their potential applications in medicinal chemistry [33,34,35,36,37,38].Pyrrolopyrimidines display a broad applicability in medicinal chemistry exhibiting antimicrobial [39,40,41,42,43], antitumour [44,45,46,47,48,49,50,51,52,53,54,55,56,57,58], antiasthmatic [59], antihypertensive [60], and anti-inflammatory [61] activities. Several method have been developed for synthesizing pyrrolopyrimidines in the last few years [62,63,64,65,66,67,68,69,70].We recently reported an efficient and convenient procedure for the preparation of pyrrolo[1,2-a]pyrimidines starting from 2-aminonorbornene hydroxamic acids [31]. The synthesis was based on the domino ring-closure reaction of hydroxamic acids with oxocarboxylic acids, followed by RDA reaction of the tetracyclic intermediates.The present target derivatives were planned to be prepared by a two-step strategy: first, the domino ring-closure reaction of diendo- and diexo-2-aminonorbornene hydroxamic acid with levulinic acid and α-ketoglutaric acid was carried out, followed by the second step involving the RDA reaction of the formed tetracycles by the loss of cyclopentadiene.Domino reactions with hydroxamic acids are not well-documented in the literature. There are examples for the main simple ring-closures with cyclic anhydrides [19], aldehydes [71], sodium nitrite [20], carbon disulfide [72], formic acid, or acetyl chloride [17].Our present aim was (i) to examine the domino ring-closure reaction of diendo- and diexo-aminonorbornene hydroxamic acids 1 and 2, (ii) to develop the retro Diels-Alder reaction of the tetracyclic heterocycles formed, and to extend this methodology to obtain novel racemic and enantiomeric pyrrolo[1,2-a]pyrimidine derivatives.
2. Results and Discussion
Racemic diendo- and diexo-2-aminonorbornene hydroxamic acids (±)-1 and (±)-2 were prepared from the appropriate ester bases with aqueous hydroxylamine solution according to an earlier procedure [31]. The enantiomers of 2-aminonorbornene hydroxamic acid (+)-1, (–)-1, (+)-2, and (–)-2 were prepared from racemic esters via diastereomeric salt formation with O,O’-di-p-toluoyl-tartaric acid (DPTTA) and O,O’-di-benzoyl-tartaric acid (DBTA) as previously described [31].In the optimization experiments of the domino reactions of levulinic acid and α-ketoglutaric acid with racemic diendo-2-aminonorbornene hydroxamic acid (±)-1 and diexo-2-aminonorbornene hydroxamic acid (±)-2, conventional heating or microwave irradiation was applied. The reaction time was significantly shorter in the microwave reactor: the best results were achieved in ethanol stirred at 100 °C for 1 h.In the domino reaction of 1 and 2 with levulinic acid and α-ketoglutaric acid, the first Schiff base A is produced, which undergoes a ring-closure reaction to produce the quinazoline epimers B and C, which are formed from A through a ring-chain tautomerism. The second ring-closure involves epimers B and C that yields compounds D and E (Scheme 1) [68].
Scheme 1
The domino reaction pathway.
The NMR spectra revealed the formation of two diastereomers of the methanopyrrolo[1,2-a]quinazolines D and E (Scheme 1). Unfortunately, we were not able to separate the diastereomers by column chromatography despite the use of a range of eluent combinations (for example: EtOAc, EtOAc/hexane = 1:1, EtOAc/MeOH = 9:1, CHCl3/MeOH = 9:1, or toluene/MeOH = 4:1). Fortunately, after derivatization with diazomethane, the diastereomers (±)-3a, (±)-3b and (±)-4a, (±)-4b could be easily separated by column chromatography eluted with EtOAc (Scheme 2).
Scheme 2
Synthesis of (+)-5 and (–)-5: (i) α-ketoglutaric acid, 1 h, 100 °C, EtOH, Microwave irradiation (MW); (ii) MeOH, diazomethane/Et2O, Room temperature (r.t.) (iii) separation of major (–)-3a, (–)-4a and minor (–)-3b, (+)-4b epimers by column chromatography (epimeric ratio 3a:3b =5:4, 4a:4b = 5:4, eluent: EtOAc) (iv) MW, 20 min, 250 °C, 300 W (v) column chromatography (eluent: EtOAc).
The stereochemistry of (±)-3a and (±)-4b was confirmed by X-ray diffraction analysis. The relative configuration of the COOCH3 group at C-3a and the bridgehead hydrogens of C-5a and C-9a have the same steric orientation in the (±)-3a and (±)-4b tetracyclic derivatives (Figure 1 and Figure 2).
Figure 1
Oak Ridge Thermal Ellipsoid Plot (ORTEP) plot of the X-ray structure of (±)-3a.
Figure 2
ORTEP plot of the X-ray structure of (±)-4b.
In order to produce racemic pyrrolo[1,2-a]pyrimidine 5, the retro Diels-Alder reaction of the methanopyrrolo[1,2-a]quinazoline derivatives was examined in the microwave reactor under varied conditions. The best results for the cycloreversion were achieved in 1,2-dichlorobenzene (DCB) at 250 °C (20 min).The synthetic method described above was extended for the preparation of the enantiomerically pure substances, via the protocol described for the racemic substances. The domino ring-closure reaction of diendo-2-aminonorbornene hydroxamic acid enantiomer (+)-1 resulted in (–)-3a and (–)-3b, while that with the diexo-2-aminonorbornene hydroxamic acid enantiomer (+)-2 resulted in epimers (–)-4a and (+)-4b. After their separation, the RDA reactions of tetracycles could easily be achieved, resulting in pyrrolo[1,2-a]pyrimidine (+)-5 and (–)-5 (Scheme 2).We attempted to use the same methodology to synthesize racemic 8. In this case, however, the ring-closure reaction with levulinic acid resulted in only a small quantity of the minor diastereomers (±)-6b and (±)-7b, which could not be isolated. The stereochemistry of (±)-6a was confirmed by X-ray diffraction analysis. The relative configuration of the CH3 group at the C-3a asymmetric centre and the bridgehead hydrogens of C-5a and C-9a have the same steric orientation in (±)-6a (Figure 3).
Figure 3
ORTEP plot of the X-ray structure of (±)-6a.
We selected an economically better approach for the synthesis of (+)-8 and (–)-8. Namely, we carried out the cycloreversions of the major methanopyrrolo[1,2-a]quinazoline derivatives (+)-6a, (–)-6a, (+)-7a, and (–)-7a and isolated the pyrrolo[1,2-a]pyrimidines (+)-8 and (–)-8 in 55–57% yields (see Scheme 3 and Scheme 4).
Scheme 3
Synthesis of (–)-8: (i) levulinic acid, 1 h, 100 °C, EtOH, MW; (ii) MeOH, diazomethane/Et2O, r.t.; (iii) isolation of major ((+)-6a, (+)-7a) epimers by column chromatography (eluent: EtOAc:MeOH = 9:1) (iv) Retro Diels-Alder (RDA) reaction of major epimers: MW, 220 °C, 20 min, 300 W, (v) column chromatography (eluent: EtOAc:MeOH = 9:1).
Scheme 4
Synthesis of (+)-8: (i) levulinic acid, 1 h, 100 °C, EtOH, MW; (ii) MeOH, diazomethane/Et2O, r.t.; (iii) isolation of major (–)-6a, (–)-7a) epimers by column chromatography (eluent: EtOAc:MeOH = 9:1); (iv) RDA reaction of major epimers: MW, 220 °C, 20 min, 300 W, (v) column chromatography (eluent: EtOAc:MeOH =9:1).
The absolute configuration of the newly built asymmetric centre of (+)-7a and (–)-7a was determined by chemical correlation: the absolute configurations of the starting 2-aminonorbornene hydroxamic acids, and the relative configuration of (±)-6a from the X-ray diffraction analysis was known. When (+)-7a was heated under the RDA reaction conditions, (–)-8 was gained. In addition, the RDA product of (+)-6a also afforded (–)-8. In contrast, when (–)-7a and (–)-6a were treated under the RDA reaction conditions, (+)-8 was formed. The NMR and HPLC data (retention times: (–)-8: 41.91 min, opposite enantiomer (+)-8: 34.19 min) and comparison of the optical rotations revealed that the final compound was identical to that of (R)-1-methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione (–)-8. Since this asymmetric centre was not affected during the RDA reaction, these results allow for the assumption that the absolute configuration of position 3a of (+)-7a is R, and that of (–)-7a is S.
3. Materials and Methods
3.1. General Methods
1H-NMR spectra were recorded at 400.13 MHz or 600.20 MHz and the 13C-NMR spectra were recorded at 100.62 MHz or 150.92 MHz in CDCl3 at ambient temperature, with a Bruker AM 400 or Bruker AV 600 spectrometer (Bruker Biospin, Karlsruhe, Germany). Chemical shifts are given in δ (ppm) relative to TMS as the internal standard. Microwave-promoted reactions were performed in sealed reaction vials (10 mL) in a microwave (CEM, Discover SP) cavity (CEM Corporation, Matthwes, NC, USA). Optical rotations were measured with a Perkin-Elmer 341 polarimeter (Perkin Elmer, Shelton, CT, USA). Mass spectra were recorded with a Micromass Q-TOF Premier mass spectrometer (Waters Corporation, Milford, MA, USA). Melting points were measured with a Hinotek-X4 micro melting point apparatus (Hinotek, Ningbo, China) and are uncorrected. Racemic 2-aminonorbornene hydroxamic acids (±)-1 and (±)-2 and enantiomeric 2-aminonorbornene hydroxamic acids (+)-1, (–)-1, (+)-2, and (–)-2 were prepared by a literature method [31]. The ee values of (+)-1, (–)-1, (+)-2, and (–)-2 were determined by HPLC by a literature method [73]. CCDC-1508562-1508564 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.The ee values of (–)-3a, (–)-3b, (–)-4a, and (+)-4b were determined by HPLC using a Chiralcel-OD-H column (Daicel corporation, Tokyo, Japan). The analytical conditions were as follows: eluent: a mixture of hexane and EtOH (75:25) with 0.1% diethylamine, flow rate: 0.4 mL∙min−1, detection at 220 nm retention times: (−)-3a: 18.82 min (antipode: 22.16 min), (–)-3b: 19.84 min (antipode: 24.23 min), (+)-4a: 20.74 min (antipode: 17.48 min), (–)-4b: 24.22 min (antipode: 20.97 min). (+)-6a, (–)-6a, (+)-7a, and (–)-7a were determined using a Phenomenex-IA column (Phenomenex, Torrance, CA, USA) eluted by a mixture of hexane and IPA (70:30), flow rate: 0.4 mL∙min−1, detection at 220 nm, retention times: (+)-6a: 32.94 min, (–)-6a: 39.46 min, (+)-7a: 31.39 min, (–)-7a: 35.39 min). The ee values of the final products of (+)-5, (–)-5, (+)-8, and (–)-8 were determined by HPLC using a Phenomenex-IA column. The analytical conditions were as follows: eluent: a mixture of hexane and IPA (70:30), flow rate: 0.4 mL∙min−1, detection at 220 nm, retention times: (+)-5: 47.97 min, (–)-5: 57.79 min, (+)-8: 34.19 min, (–)-8: 41.91 min.1H-NMR and 13C-NMR spectra of compounds (–)-3a, (–)-3b, (–)-4a, (+)-4b, (+)-5 (+)-6a, (+)-7a and (+)-8, HPLC chromatogram of compounds (±)-5, (–)-5, (+)-5 (±)-8 (–)-8, (+)-8, and table for X-ray crystallography data for (±)-3a, (±)-4a and (±)-6a are available in the Supplementary materials.
3.2. Synthesis of New Compounds
3.2.1. Synthesis of Methanopyrrolo[1,2-a]quinazoline Derivatives (–)-3a, (–)-3b, (–)-4a, and (+)-4b
A mixture of 2-aminonorbornene hydroxamic acid (+)-1 or (+)-2 (336 mg, 2 mmol), and α-ketoglutaric acid (292 mg, 2 mmol) was dissolved in 6 mL EtOH in a 10 mL pressurized reaction vial and the solution was stirred at 100 °C for 1 h at max 300 W microwave irradiation. Then the reaction mixture was evaporated to dryness and the crude product was crystallized from Et2O. The crystals isolated were dissolved in MeOH and a diazomethane/Et2O mixture was added dropwise to the solution at ambient temperature and was stirred for 30 min. The reaction was followed by TLC. (Diazomethane is a very harmful and hazardous reagent and must be handled with caution! This reaction should be performed in a well-ventilated hood!) The solvent was then removed by evaporation and the residue was dissolved in 2 mL EtOAc and transferred to a silica gel column (Merck, Darmstadt, Germany) and eluted with EtOAc. The product was crystallized from iPr2O to produce white crystals.Methyl (3aS,5aS,6R,9S,9aR)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]quinazoline-3a-carboxylate [(–)- White crystals (39% yield), m.p. 125–128 °C,
= –92.5 (c = 0.33, EtOH), ee 87%, 1H-NMR (400 MHz, CDCl3, 30 °C): 1.36–1.38 (m, 1H, 11-H), 1.58–1.60 (m, 1H, 11-H), 2.13–2.21 (m, 1H, CH2), 2.45–2.51 (m, 1H, CH2), 2.58–2.74 (m, 2H, CH2), 3.09–3.12 (m, 1H, 5a-H), 3.43 (m, 1H, 9-H), 3.82 (s, 3H, COOCH3), 3.85 (s, 3H, OCH3), 3.93–3.95 (m, 1H, 9a-H), 4.06 (m, 1H, 6-H), 6.07–6.09 (m, 1H, 8-H), 6.20–6.22 (m, 1H, 7-H), 13C-NMR (100 MHz, CDCl3, 30 °C): δ = 28.1, 30.1, 41.1, 46.6, 46.9, 46.9, 47.3, 54.0, 54.6, 65.3, 82.3, 135.7, 136.1, 170.0, 172.3, 173.9, HRMS calcd. for [M + H+] m/z = 307.1294, measured: m/z = 307.1288.Methyl (3aR,5aS,6R,9S,9aR)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]quinazoline-3a-carboxylate [(–)- White crystals (44% yield), m.p. 170–172 °C, = −3.8 (c = 0.30, EtOH), ee 97%, 1H-NMR (600 MHz, CDCl3, 30 °C): 1.44–1.45 (m, 1H, 11-H), 1.56–1.63 (m, 1H, 11-H), 2.24–2.30 (m, 1H, CH2), 2.46–2.50 (m, 2H, CH2), 2.79–2.85 (m, 1H, CH2), 3.25–3.28 (m, 2H, 5a-H, 9-H), 3.42 (m, 1H, 6-H), 3.78 (s, 3H, COOCH3), 3.89 (s, 3H, OCH3), 4.68–4.69 (m, 1H, 9a-H), 5.73–5.75 (m, 1H, 8-H), 6.19–6.20 (m, 1H, 7-H), 13C-NMR (100 MHz, CDCl3, 30 °C): δ = 29.2, 32.1, 45.1, 46.3, 47.2, 48.9, 52.9, 53.1, 64.3, 81.6, 134.2, 138.6, 168.4, 170.3, 174.9, HRMS calcd. for [M + H+] m/z = 307.1294, found m/z = 307.1288.Methyl (3aS,5aR,6R,9S,9aS)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]quinazoline-3a-carboxylate [(–)- White crystals, (44% yield), m.p. 125–128 °C,
= −64 (c = 0.30, EtOH), ee 97% 1H-NMR (600 MHz, CDCl3, 30 °C): 1.39–1.40 (m, 1H, 11-H), 1.49–1.50 (m, 1H, 11-H), 2.40–2.56 (m, 3H, CH2), 2.65–2.81 (m, 3H, CH2, 5a-H, 9-H), 3.34 (m, 1H, 6-H), 3.84 (s, 3H, COOCH3), 4.02 (s, 3H, OCH3), 4.15 (m, 1H, 9a-H), 6.23–6.25 (m, 1H, 7-H), 6.31–6.33 (m, 1H, 8-H), 13C-NMR (150 MHz, CDCl3, 30 °C): δ = 29.1, 30.9, 44.4, 44.8, 46.9, 47.5, 51.9, 53.4, 64.0, 81.6, 137.6, 138.4, 167.7, 170.9, 173.9, HRMS calcd. for [M + H+] m/z = 307.1294, found m/z = 307.1288.Methyl (3aR,5aR,6R,9S,9aS)-4-methoxy-1,5-dioxo-1,2,3,3a,4,5a,6,9a-decahydro-6,9-methanopyrrolo[1,2-a]quinazoline-3a-carboxylate [(+)- White crystals, (39% yield), m.p. 170–172 °C,
= + 6.5 (c = 0.33, EtOH), ee 81%, 1H-NMR (600 MHz, CDCl3, 30 °C): 1.51–1.52 (m, 2H, 11-H), 2.25–2.30 (m, 1H, CH2), 2.58–2.82 (m, 4H, CH2, 5a-H), 3.35 (m, 1H, 9-H), 3.39–3.40 (m, 1H, 6-H), 3.81 (s, 3H, COOCH3), 3.94 (s, 3H, OCH3), 3.99 (m, 1H, 9a-H), 6.17–6.19 (m, 1H, 7-H), 6.33–6.34 (m, 1H, 8-H), 13C-NMR (150 MHz, CDCl3, 30 °C): δ = 27.9, 30.1, 43.7, 44.6, 46.6, 47.7, 53.7, 54.3, 65.0, 82.0, 135.7, 138.6, 169.4, 173.2, 174.1, HRMS calcd. for [M + H+] m/z = 307.1294, found m/z = 307.1288.
3.2.2. Synthesis of Pyrrolo[1,2-a]pyrimidines (+)-5 and (–)-5
Tetracyclic compound (–)-3a, (–)-4a, or (–)-3b and (+)-4b (50 mg, 0.16 mmol,) was dissolved in 2 mL DCB in a 10 mL sealed reaction vial. The solution was stirred at 250 °C for 20 min at max 300 W microwave irradiation. Then the solvent was evaporated, the residue was dissolved in 2 mL EtOAc/MeOH = 9:1, and was purified by column chromatography on silica gel eluted by EtOAc/MeOH = 9:1. The product was crystallized from iPr2O to produce white crystals.Methyl (R)-1-methoxy-2,6-dioxo-1,2,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrimidine-8a-carboxylate [(+)- White crystals, (41% yield), m.p. 156–158 °C, = +145 (c = 0.16, EtOH), ee 95%, 1H-NMR (600 MHz, CDCl3, 30 °C): 2.46–2.52 (m, 1H, CH2), 2.70–2.74 (m, 1H, CH2), 2.83–2.98 (m, 2H, CH2), 3.82 (s, 3H, OCH3), 3.96 (s, 3H, OCH3), 5.41 (d, J = 7.39 Hz, 1H, 3-H), 7.33 (d, J = 7.61 Hz, 1H, 4-H) 13C-NMR (150 MHz, CDCl3, 30 °C): δ = 28.8, 30.0, 53.7, 66.0, 81.1, 104.7, 131.1, 165.5, 168.8, 170.6, HRMS calcd. for [M + H+] m/z = 241.0825, found m/z = 241.0819.Methyl (S)-1-methoxy-2,6-dioxo-1,2,6,7,8,8a-hexahydropyrrolo[1,2-a]pyrimidine-8a-carboxylate [(–)- White crystals, (40% yield), m.p. 155–156 °C, = −139 (c = 0.16, EtOH), ee 99% 1H- and 13C-NMR is similar to (+)-5.
3.2.3. Synthesis of Methanopyrrolo[1,2-a]quinazoline Derivatives (+)-6a, (–)-6a, (+)-7a, and (–)-7a
A mixture of 2-aminonorbornene hydroxamic acid (+)-1, (–)-1, (+)-2, or (–)-2 (336 mg, 2 mmol) and levulinic acid (232 mg, 2 mmol) was dissolved in 6 mL EtOH and heated in a 10 mL pressurized reaction vial and the solution was stirred at 100 °C for 1 h at max 300 W microwave irradiation. After that the reaction mixture was evaporated to dryness and the resulting oil was dissolved in dichloromethane and was extracted with 15 mL 20% NaOH solution. The water phase was acidified with 20% HCl solution and extracted with dichloromethane. The organic phase was dried (Na2SO4) and evaporated. The gained yellow oil was dissolved in MeOH and a solution of diazomethane in Et2O was added in a flask protected from light, at room temperature for about 30 min, until no starting material could be observed by TLC. (Diazomethane is a very harmful and hazardous reagent and must be handled with caution! This reaction should be performed in a well-ventilated hood!) The solvent was then removed by evaporation and the residue was dissolved in EtOAc:MeOH = 9:1 (3 mL). The resulting solution was transferred to a silica gel column and eluted with EtOAc:MeOH = 9:1 and the diastereomers were separated. The products were crystallized from iPr2O to afford white crystals.(3aR,5aS,6R,9S,9aR)-4-methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione [(+)- White crystals (29% yield), m.p. 158–161 °C, = +23.1 (c = 0.44, EtOH), ee 99%, 1H-NMR (400 MHz, CDCl3, 30 °C): 1.39 (m, 1H, 11-H), 1.53 (s, 3H, CH3) 1.57–1.60 (m, 1H, 11-H), 2.12–2.16 (m, 2H, CH2), 2.38–2.44 (m, 2H, CH2), 3.00–3.04 (m, 1H, 5a-H), 3.45 (m, 1H, 9-H), 3.84 (s, 3H, OCH3), 4.03–4.06 (m, 1H, 9a-H), 4.11 (m, 1H, 6-H), 6.09–6.11 (m, 1H, 8-H), 6.18–6.20 (m, 1H, 7-H), 13C-NMR (100 MHz, CDCl3, 30 °C): δ = 23.9, 29.5, 30.8, 45.8, 46.4, 47.0, 48.6, 52.8, 64.8, 80.3, 135.3, 135.6, 170.8, 172.3, HRMS calcd. for [M + H+] m/z = 263.1396, found m/z = 263.1390.(3aS,5aR,6S,9R,9aS)-4-methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione [(–)- White crystals (32% yield), m.p. 157–159 °C, = −22.9 (c = 0.44, EtOH), ee 98%, 1H- and 13C-NMR is similar to (+)-6a.(3aR,5aS,6S,9R,9aR)-4-methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione [(+)- White crystals, (28% yield), m.p. 141–142 °C, = +62.3 (c = 1.12, EtOH), ee =87%, 1H-NMR (400 MHz, CDCl3, 30 °C): 1.61–1.64 (m, 1H, 11-H), 1.68 (m, 3H, CH3), 1.80–1.83 (m, 1H, 11-H), 2.17–2.33 (m, 2H, CH2), 2.42–2.55 (m, 2H, CH2), 2.60–2.63 (m, 1H, 5a-H), 2.81 (m, 1H, 9-H), 3.36 (m, 1H, 6-H), 3.91 (s, 3H, OCH3), 4.17–4.19 (m, 1H, 9a-H), 6.19–6.20 (m, 1H, 7-H), 6.39–6.41 (m, 1H, 8-H), 13C-NMR (100 MHz, CDCl3, 30 °C): δ = 22.9, 30.2, 31.3, 44.0, 45.0, 46.3, 48.5, 53.5, 65.3, 81.1, 136.5, 138.7, 166.4, 173.2, HRMS calcd. for [M + H+] m/z = 263.1396, found m/z = 263.1390.(3aS,5aR,6R,9S,9aS)-4-methoxy-3a-methyl-2,3,3a,4,5a,6,9a-octahydro-6,9-methanopyrrolo[1,2-a]quinazoline-1,5-dione [(–)- White crystals, (31% yield), m.p. 138–141 °C = −72.3 (c = 1.18, EtOH), ee 91% 1H- and 13C-NMR is similar to (+)-7a.
3.2.4. Synthesis of Pyrrolo[1,2-a]pyrimidines (+)-8 and (–)-8
Tetracyclic compound (+)-6a, (+)-7a, (–)-6a, or (–)-7a (50 mg, 0.19 mmol) was dissolved in 2 mL DCB in a 10 mL sealed reaction vial. The solution was stirred at 240 °C for 20 min at max 300 W microwave irradiation. Then the solvent was evaporated, and the residue was dissolved in 2 mL EtOAc and purified by column chromatography on silica gel eluted by EtOAc. The product was crystallized from iPr2O to produce white crystals.(S)-1-methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione [(+)- White crystals, (55% yield), m.p. 137–140 °C, = +158 (c = 0.23, EtOH), ee 99 %, 1H-NMR (400 MHz, CDCl3, 30 °C): 1.49 (m, 3H, CH3), 2.37–2.46 (m, 2H, CH2), 2.51–2.69 (m, 2H, CH2), 3.89 (s, 3H, OCH3), 5.35 (d, J = 7.71 Hz, 1H, 3-H), 7.31 (d, J = 7.62 Hz, 1H, 4-H), 13C-NMR (100 MHz, CDCl3, 30 °C): δ = 18.4, 30.0, 32.4, 65.5, 80.8, 104.3, 131.4, 166.3, 171.6, HRMS calcd. for [M + H+] m/z = 197.0926, measured: m/z = 197.0916.(R)-1-methoxy-8a-methyl-1,7,8,8a-tetrahydropyrrolo[1,2-a]pyrimidine-2,6-dione[(–)-]: White crystals, (57% yield), m.p. 139–142 °C; = –152 (c = 0.23, EtOH), ee 99%, 1H- and 13C-NMR is similar to (+)-8.
4. Conclusions
In conclusion, new racemic and enantiomeric pyrrolo[1,2-a]pyrimidines were synthesized starting from diendo- and diexo-2-aminonorbornene hydroxamic acids. Their domino ring closure reactions with α-ketoglutaric acid and levulinic acid, and the formation of two diastereomers were observed in each case. After separation by column chromatography, single diastereomers were subjected to a microwave-mediated RDA reaction and gained bicyclicpyrrolo[1,2-a]pyrimidines through the loss of cyclopentadiene. When enantiomeric diexo- or diendo-3-amino-N-hydroxybicyclo[2.2.1]hept-5-ene-2-carboxamides were used, the products were enantiomeric heterocycles with ee = 95–99%, demonstrating that the starting compounds are excellent chiral sources, and the stereochemical information can be effectively transferable to the newly formed stereogenic centre.
Authors: Vidya P Kumar; Jose A Cisneros; Kathleen M Frey; Alejandro Castellanos-Gonzalez; Yiqiang Wang; Aleem Gangjee; A Clinton White; William L Jorgensen; Karen S Anderson Journal: Bioorg Med Chem Lett Date: 2014-07-24 Impact factor: 2.823
Authors: R C Mishra; Renu Tripathi; Diksha Katiyar; Neetu Tewari; Deepti Singh; R P Tripathi Journal: Bioorg Med Chem Date: 2003-12-01 Impact factor: 3.641
Authors: Lan Zhao; Chien-Nien Chen; Nabil Hajji; Eduardo Oliver; Emanuele Cotroneo; John Wharton; Daren Wang; Min Li; Timothy A McKinsey; Kurt R Stenmark; Martin R Wilkins Journal: Circulation Date: 2012-06-18 Impact factor: 29.690